Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Stannus Protoporphyrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Renibus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Cascade Chemistry has been selected by Renibus Therapeutics, to produce the API for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of high risk COVID-19 patients.
Brand Name : RBT-9
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Stannus Protoporphyrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Renibus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ifenprodil Tartrate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Algernon has made the decision to scale-up cGMP manufacturing of Ifenprodil to support its quickly evolving clinical program for acute lung injury in COVID-19 patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 23, 2020
Lead Product(s) : Ifenprodil Tartrate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?